治験レーダーAI | ||
|---|---|---|
治験 NCT01505673(対象:2型糖尿病、肥満)は完了です。詳細は治験レーダーのタイル表示と AI 発見ツールで確認するか、ここで質問してください。 | ||
フィルター基準に一致する試験が1件見つかりました
タイル表示
Adding Liraglutide to High Dose Insulin: Breaking the Cycle 第IV相・フェーズ4 71
治験(臨床試験)の詳細は主に英語で提供されていますが、治験レーダーAIがサポートします!「治験解説」をクリックして、選択した言語で試験情報を表示し、議論してください。
治験番号 NCT01505673 は 治療 の研究で、2型糖尿病、肥満 を対象とした 第IV相・フェーズ4 介入研究 臨床試験 でした。現在は 完了 です。2012年1月1日 に開始し、71 名の参加者 が参加しました。この試験は Ildiko Lingvay によって主導され、2016年6月1日 に完了しました。ClinicalTrials.gov からの最新更新日は 2018年1月16日 です。
概要
The purpose of this study is to evaluate whether the addition of liraglutide 1.8 mg/day to a high-dose insulin regimen (>1.8 units/kg/day) in patients with uncontrolled (HbA1c >7.5%) type 2 diabetes mellitus will improve blood sugar control.
It also evaluates the effect of liraglutide on liver and pancreatic fat content, explores the mechanism of blood sugar improvement by assessing weight and pancreatic hormone r...
もっと見る詳細説明
Type 2 diabetes is a progressive disease with incessant beta-cell dysfunction that often ultimately requires insulin treatment. Patients requiring high insulin dosages represent a particular treatment challenge and often have uncontrolled glycemia despite progressive dose increases and are especially prone to insulin related lipotoxicity and weight gain.
Glucagon-like peptide agonists (GLP-1) such as liraglutide hav...
もっと見る公式タイトル
Adding Liraglutide to High Dose Insulin: Breaking the Cycle
疾患名
2型糖尿病肥満刊行物
この臨床試験について発表された科学記事と研究論文:その他の研究識別子
- IIS-000235
NCT番号
開始日
2012-01
最終更新日
2018-01-16
終了予定日
2016-06
目標参加者数
71
試験の種類
介入研究
治験の相・段階
第IV相・フェーズ4
状況
完了
キーワード
Insulin
Glucagon-like peptide
Liraglutide
Beta-Cell
pancreatic steatosis
hepatic steatosis
Glucagon-like peptide
Liraglutide
Beta-Cell
pancreatic steatosis
hepatic steatosis
主目的
治療
割付方法
無作為化
介入モデル
並行割当
盲検化
三重盲検
群(アーム)/介入
| 参加グループ/群 | 介入/治療法 |
|---|---|
実薬対照薬Liraglutide | Liraglutide Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months |
プラセボ対照薬Saline injection | 生理食塩水 Placebo injection of 1.8mg saline once daily for 6-months |
主要評価項目
副次評価項目
| 評価指標 | 指標の説明 | 時間枠 |
|---|---|---|
Glycemic Control Measured by HbA1c | HbA1c (%) | 6-months |
| 評価指標 | 指標の説明 | 時間枠 |
|---|---|---|
Pancreatic and Hepatic Triglyceride Content | Liver Triglyceride and Pancreatic Triglyceride | 6-months |
Weight | 6-months | |
Beta-Cell Function | Fasting Glucose as a Measure of Beta-Cell Function | 6-months |
Glucagon | Measured during mixed meal challenge test. | 6-months |
Total Daily Insulin Dose | The 3 days average of the total daily dose of insulin used within 3 consecutive days prior office visit 6 month. | 6-months |
Number of Daily Injections | The 3 days average of the number of daily injections performed within 3 consecutive days prior office visit 6 month. | 6-months |
Blood Pressure | 6-months | |
Lipid Profile | 6-months | |
Liver Function Blood Test | 6-months | |
Hypoglycemic Events | Reported as hypoglycemic events per month by patient as any blood glucose \<70 mg/dl or symptoms of hypoglycemia with blood glucose \>70 mg/dl | 6-months |
Quality of Life Survey (QoL) - General Health Perception | General health perception was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 = excellent; 2 = very good; 3 = good; 4 = fair; 5 = poor. | 6-months |
Beta-Cell Function | Fasting C-peptide as a Measure of Beta-Cell Function | 6 months |
Matsuda Index as a Measure of Beta Cell Function | The Matsuda index is a measure of insulin sensitivity and has no minimum/maximum values. Index values are calculated as 500,000/square root of ((fasting glucose x fasting c-peptide x 333) x (mean 120 min post-meal glucose x mean 120 min post-meal c-peptide x 333)). Higher/lower values = better/worse insulin sensitivity. | 6 months |
Beta-cell Function | AUC c-peptide | 6 Months |
Ratio (AUC C-peptide/AUC Glucose) | 6 months | |
AUC Glucose | 6 months | |
Quality of Life Survey (QoL) - Current Health Perception | Current health perception was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 = much better than 3 months ago; 2 - Somewhat better now than 3 months ago; 3 - About the same; 4 - Somewhat worse now than 3 months ago; 5 Much worse now than 3 months ago. | 6 months |
Quality of Life Survey (QoL) - Treatment Satisfaction | Quality of Life Survey (QoL) - treatment satisfactionTreatment satisfaction was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 - very satisfied; 2 - moderately satisfied; 3 - neither satisfied nor dissatisfied; 4 - moderately dissatisfied; 5 - very dissatisfied. | 6 months |
Quality of Life Survey (QoL) - Treatment Impact | Treatment impact was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 - very satisfied; 2 - moderately satisfied; 3 - neither satisfied nor dissatisfied; 4 - moderately dissatisfied; 5 - very dissatisfied. | 6 months |
Quality of Life Survey (QoL) - Social or Vocational Worry | Social or vocational worry was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 0-5, where 0 - does not apply; 1 - never; 2 - seldom; 3 - sometimes; 4 - often; 5 - all of the time. | 6 months |
Quality of Life Survey (QoL) - Hypoglycemia Fear | Hypoglycemia fear was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1-5, where 1 - never worry; 2 - rarely water; 3 - sometimes worry; 4 - often worry; 5 - very often worry. | 6 months |
Quality of Life Survey (QoL) - Glycemia Control Perception | Glycemia control perception was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1-7, where 1 - extremely controlled and 7 - not at all controlled. | 6 months |
Quality of Life Survey (QoL) - Lifestyle Flexibility | Lifestyle flexibility was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1 to 5, where 1 - a great deal of choice; 2 - a lot of choice; 3 - some choice; 4 - a little choice; 5 - no choice. | 6 months |
Quality of Life Survey (QoL) - Social Stigma | Social stigma was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a Likert scale score of 1 to 5, where 1 strongly agree; 2 - somewhat agree; 3 - neither agree nor disagree; 4 - somewhat disagree; 5 - strongly disagree. | 6 months |
Quality of Life Survey (QoL) - Satisfaction With Insulin Treatment | Satisfaction with insulin treatment was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1 to 7, where 1 extremely satisfied to 7 - not at all satisfied. | 6 months |
Quality of Life Survey (QoL) - Willingness to Continue Insulin Treatment | Willingness to continue insulin treatment was measured at randomization and 6 months later using the modified Diabetes Quality of Life Clinical Trial Questionnaire. This questionnaire addresses several areas with respect to diabetes QoL. Answers are in the form of a scale score of 1 to 7, where 1 extremely willing to 7 - not at all willing. | 6 months |
適格基準
対象年齢
成人, 高齢者
試験の最低年齢
18 Years
対象性別
全て
- Type 2 diabetes mellitus
- Insulin dose of >1.8 units/kg/day (represents total daily insulin dose, regardless of formulation, regimen, number of daily shots)
- HbA1c ≥ 7.5% and ≤ 11%
- Age ≥ 18
- Stable comorbidities on stable treatment regimens
- Stable dose of all oral hypoglycemics for ≥ 3 months prior to enrollment
- Ability to provide informed consent before any trial-related activities
- Type 1 diabetes mellitus
- Any contraindication to the MRI procedure (metallic implants, severe claustrophobia, pregnancy, unable to lie still on a hard table for the duration of the procedure, weight above 400 lb - limit of the MRI table, magnet's inner circumference smaller than the largest body circumference)
- History of any pancreatic disease as it might interfere with the pancreatic TG measurement (i.e. pancreatitis, tumors, cysts, type 1 diabetes, any pancreatic surgery)
- End Stage Renal Disease on dialysis due to increased risk of hypoglycemia, and possible interference with accurate measurement of HbA1c
- Incretin therapy (any GLP-1 agonist or DPP-IV inhibitor)
- Unstable or decompensated comorbidities
- Personal or family history of medullary thyroid carcinoma or MEN-2 syndrome
- Severe gastroparesis
- Pregnancy, breast feeding, intention to become pregnant, or not using adequate contraceptive measures
- Organ transplant recipient or waiting list candidate
- Steroid use (current or potential use during the trial)
- Known/suspected allergy to trial medication, excipients, or related products
- Contraindications to study medications, worded specifically as stated in the product's prescribing information
- Non-English speaking volunteers since no interpreters are available and the safety of the volunteers could be jeopardized if adequate and reliable communication is not possible.
責任者
Ildiko Lingvay, 治験依頼者・主任研究者, Assistant Professor, University of Texas Southwestern Medical Center
連絡先情報がありません。
1 1カ国の場所
Texas
UT Southwestern, Dallas, Texas, 75390, United States